ABBV News and Press, AbbVie Inc.

2024-06-29 15:44:55 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End ...

2024-06-28 09:29:56 ET More on AbbVie, Genmab, etc. AbbVie: 5 Reasons That Make A Buy Case AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie buys bowel...

AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma PR Newswire If approved, epcoritamab (TEPKINLY ® ) will become the first and only bispecific antibody conditionally approv...

2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...

2024-06-27 14:07:44 ET More on Coherus BioSciences Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript Coherus BioSciences Non-GAAP EPS of -$0.32 misses by $0.11, revenue of $7...

2024-06-27 14:02:20 ET More on S&P 500 Index: The Greenback Consolidates While Sustaining A Break Against The Yen Fed Update: The Fed Has A Mortgage-Backed Securities Problem Market Breadth Will Improve As The Soft Landing Comes Into View Nasdaq, S&P,...

2024-06-27 13:40:30 ET More on Cerevel Therapeutics Cerevel Therapeutics: Time For A Risk Arbitrage Play? Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal Cerevel Therapeutics seesaws amid FTC notice on closed door meeting Seeking Alpha...

2024-06-27 11:27:19 ET Summary Immunome, Inc. stock surged over 400% post-merger and management changes but has since dropped over 60% as initial enthusiasm has waned. The company's new CEO has drawn attention to the company, which has one asset, AL102, in clinical evaluation for ...

2024-06-27 09:48:45 ET More on AbbVie AbbVie: 5 Reasons That Make A Buy Case AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) Genmab, AbbVie win FDA nod for ...

AbbVie Acquires Celsius Therapeutics PR Newswire Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. , June 27, ...